Standard strategies for acute ischemic stroke within the rtPA therapeutic window
Finland
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published June 10, 2013.
Author Disclosures
- Turgut Tatlisumak, MD, PhD
- Turgut Tatlisumak, MD, PhD
Boehringer-Ingelheim Mitsubishi Pharma PhotoThera BrainsGate H. Lundbeck A/S Orion Pharma
NONE
Boehringer Ingelheim (travel expenses to 1 conference) Professio Finland (speaker honoraria) University of Helsinki (speaker honoraria) Finnish Medical Association (speaker honoraria) University of Donau (Austria, speaker honoraria) Genzyme Oy (Finland, speaker honoraria) Finnish Neurological Association (speaker honoraria) Australia-NZ Stroke Association (speaker honoraria) Congress traveling and accommodation costs: European Stroke Conference European Federation of Neurological Societies European Stroke Organisation LANTEL telemedicine conference (France) University of Rostock (Germany) University of Bielefeld (Germany) SITS International Boehringer Ingelheim University of Donau (Austria) Catholic University of Leuven (Belgium) Austrian Stroke Society University of Oulu (Finland) Nordic Stroke Conference Australia-NZ Stroke Association
Stroke, 2000-2006, 2010- Current Vascular Pharmacology, 2002- The Open Pharmacology Journal 2007-2010 Clinics of Turkey 2007- Clinics of Turkey / Neurology 2007- The Open Cardiovascular Medicine Journal 2007- Recent Patents on Biotechnology 2008- Recent Patents on CNS Drug Discovery, 2008-2010 Experimental and Translational Stroke Medicine, 2008-2009 Stroke Research and Treatment, 2009- BMC Journal of Experimental and Translational Stroke Medicine, 2009- Frontiers in Stroke, 2010- Case Reports in Neurology (founding editor-in-chief)2009- 2012 Cerebrovascular Diseases, 2011- No compensation was received for any of the above editorial duties
1. Stanniocalcin proteins and nucleic acids and methods based thereon. Application No/ Patent No: WO0130969, Publication date: 2001-05-03, requested patent: EP1233778, Inventors: Olsen HS, Zhang K, Lindsberg P, Tatlisumak T, Kaste M, Andersson LC. Human Genome Sciences Inc (US), Application number: WO2000US29432 200001026 2. New Therapeutic Uses (method to prevent brain edema and reperfusion injury), PCT/FI2004/000070. Inventors: Lindsberg PJ, Karjalainen-Lindsberg M-L, Tatlisumak T, Strbian D. Applicant: Licentia Oy. Application date: February 13, 2003. Publication 7/2003, Application number: 20030224. 3. Thrombolytic compositions (method to prevent postthrombolytic hemorrhage formation), PCT/FI2004/000071. Inventors: Lindsberg PJ, Karjalainen- Lindsberg M-L, Tatlisumak T, Strbian D, Kovanen P. Applicant: Licentia Oy. Application date: February 13, 2003. Publication: 3/2003. Application number: 20030225.
NONE
NONE
Boehringer Ingelheim, PhotoThera, BrainsGate, H. Lundbeck A/B, Orion
NONE
I was in capacity of receiving for editing 1 book for Cambridge Univ Press (donated to British Red Cross) and being an editor-in-chief for Case Reports in Neurology Journal (donated to Swiss Red Cross).
NONE
NONE
Helsinki University Central Hospital Research Funds European Union, EU FP7 202213, 2008-2012, PI Biocentrum Finland, 2010-2012 Biocentrum Helsinki, 2011, 2012, 2013 Finnish Academy of Sciences, 2012-2014
NONE
Sigrid Juselius Foundation, 2010, PI Maire Taponen Foundation, 2012
NONE
NONE
NONE
NONE
NONE
NONE
- Correspondence to:
turgut.tatlisumak{at}hus.fi
Article usage
The Nerve!: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.